Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.74 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039569 | 1.00 | CYP11B2 (0.74) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039644 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041017 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039645 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041353 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039651 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL13015582 | 0.85 | CYP11B2 (0.74) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL1037474 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL30395982 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL12460772 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | CYP11B2 4077/4885CYP19A1 2165/4885CYP11B1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.